Glaucoma, Parkinson's disease and neurodegeneration

被引:0
|
作者
Balci, Sevcan Yildiz [1 ]
Eraslan, Muhsin [2 ]
Temel, Ahmet [2 ]
机构
[1] Igdir Devlet Hastanesi, Oftalmol Klin, Igdir, Turkey
[2] Marmara Univ, Tip Fak Hastanesi, Oftalmol Anabilim Dali, Ust Kaynarca, Pendik, Turkey
来源
MARMARA MEDICAL JOURNAL | 2015年 / 28卷 / 01期
关键词
Irreversible vision loss; Neurodegenerative disorders; Neuroprotective therapy;
D O I
10.5472/MMJ.2015.03691.1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Glaucoma is a disease that causes irreversible vision loss characterized by progressive retinal ganglion cell (RGC) death. The mechanisms independent of intraocular pressure are also implicated in glaucomatous degeneration pathogenesis and numerous similarities exist between glaucoma and neurodegenerative diseases such as Alzheimer's and Parkinson's diseases. Although, there is a common pathway between glaucoma and neurodegenerative disorders, pathogenesis of the relationship between neurodegenerative disorders and glaucoma remains poorly undefined. Optical coherence tomography (OCT), non-invasively quantifies the thickness of the retinal nerve fiber layer (RNFL) which is effected due to RGC damage in glaucomatous patients. Recently, RNFL thickness measurements have been studied by using OCT in several neurodegenerative conditions, including Parkinson's disease. The RNFL is unique as a model of neurodegeneration where the changes in its structure is represented with axonal damage. RNFL thickness measurements are important in neurodegenerative disorders which are characterized with neuronal loss and have common pathogenesis with glaucoma. In this review, we emphasize the relationship between glaucoma, Parkinson's disease and neurodegeneration.
引用
收藏
页码:8 / 12
页数:5
相关论文
共 50 条
  • [11] Molecular pathways of neurodegeneration in Parkinson's disease
    Dawson, TM
    Dawson, VL
    SCIENCE, 2003, 302 (5646) : 819 - 822
  • [12] Significance of neuromelanin for neurodegeneration in Parkinson's disease
    Double, KL
    Riederer, P
    Gerlach, M
    DRUG NEWS & PERSPECTIVES, 1999, 12 (06) : 333 - 340
  • [13] Molecular mechanism of neurodegeneration in Parkinson's disease
    Chung, K. K.
    NEUROSIGNALS, 2006, 15 (01) : 42 - 42
  • [14] The Paths to Neurodegeneration in Genetic Parkinson's Disease
    Abdel-Salam, Omar M. E.
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2014, 13 (09) : 1485 - 1512
  • [15] Calpain Mediated Neurodegeneration in Parkinson's disease
    Knaryan, V. H.
    NEUROCHEMICAL JOURNAL, 2023, 17 (04) : 632 - 638
  • [16] Animal models of neurodegeneration in Parkinson's disease
    Earl, C
    Sautter, J
    PARKINSON'S DISEASE, 2002, 1 : 88 - 93
  • [17] Cyclooxygenase and Neuroinflammation in Parkinson's Disease Neurodegeneration
    Bartels, Anna L.
    Leenders, Klaus L.
    CURRENT NEUROPHARMACOLOGY, 2010, 8 (01) : 62 - 68
  • [18] Neurodegeneration and cognition in Parkinson's disease: a review
    Ding, W.
    Ding, L. -J.
    Li, F. -F.
    Han, Y.
    Mu, L.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2015, 19 (12) : 2275 - 2281
  • [19] Hypothetical mechanisms of neurodegeneration in Parkinson's disease
    Ruberg, M
    FranceLanord, V
    Lambeng, N
    Nguyen, TT
    Cerqueira, E
    Brugg, B
    Michel, PP
    Hunot, S
    Faucheux, B
    Hirsch, E
    Agid, Y
    JOURNAL OF NEUROCHEMISTRY, 1997, 69 : S140 - S140
  • [20] The Role of Ceruloplasmin in Neurodegeneration in Parkinson's Disease
    Gurer, Reyhan
    Aydin, Senay
    Gokce, Dilvin
    Ayaz, Tunahan
    Isik, Nihal
    TURKISH JOURNAL OF NEUROLOGY, 2016, 22 (01) : 19 - 25